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An initial response of Staphylococcus aureus to encounter with cell wall-active antibiotics occurs by trans-
membrane signaling systems that orchestrate changes in gene expression to promote survival. Histidine kinase
two-component sensor-response regulators such as VraRS contribute to this response. In this study, we
examined VraS membrane sensor phosphotransfer signal transduction and explored the genetic consequences
of disrupting signaling by engineering a site-specific vraS chromosomal mutation. We have used in vitro
autophosphorylation assay with purified VraS[64-347] lacking its transmembrane anchor region and tested
site-specific kinase domain histidine mutants. We identified VraS H156 as the probable site of autophosphor-
ylation and show phosphotransfer in vitro using purified VraR. Genetic studies show that the vraS(H156A)
mutation in three strain backgrounds (ISP794, Newman, and COL) fails to generate detectable first-step
reduced susceptibility teicoplanin mutants and severely reduces first-step vancomycin mutants. The emergence
of low-level glycopeptide resistance in strain ISP794, derived from strain 8325 (rsbU), did not require a
functional B, but rsbU restoration could enhance the emergence frequency supporting a role for this alter-
native sigma factor in promoting glycopeptide resistance. Transcriptional analysis of vraS(H156A) strains
revealed a pronounced reduction but not complete abrogation of the vraRS operon after exposure to cell
wall-active antibiotics, suggesting that additional factors independent of VraS-driven phosphotransfer, or B,
exist for this promoter. Collectively, our results reveal important details of the VraRS signaling system and
predict that pharmacologic blockade of the VraS sensor kinase will have profound effects on blocking emer-
gence of cell wall-active antibiotic resistance in S. aureus.
Staphylococcus aureus is a major human pathogen that causes a
variety of diseases ranging from relatively minor skin infections
to invasive and systemic disease with significant morbidity and
mortality (17, 44). Of particular concern are S. aureus strains
carrying one of several allotypes of a mobile genetic element,
the SCCmec cassette, which encodes mecA, and a low-affinity
penicillin-binding protein variant, PBP2A (12). The expression
of PBP2A renders S. aureus insensitive to a broad range of
-lactams, including methicillin, hence the name MRSA (for
methicillin-resistant S. aureus). Various MRSA strains have
become endemic in hospitals and in the community prompting
worldwide efforts for detection and infection control.
Glycopeptide antibiotics (teicoplanin and vancomycin) are
considered first-line drugs for the treatment of infections due
to MRSA. The emergence of resistance (most often termed
reduced sensitivity) to glycopeptides poses a major challenge
to the treatment of MRSA infections since few clinically proven
and effective alternative therapies exist (29).
Altered sensitivity to glycopeptides occurs by two mecha-
nisms termed exogenous and endogenous. The exogenous
mechanism (VanA type) conferring high-level resistance (van-
comycin MIC  16 g/ml) occurs by the horizontal acquisition
of the vanA multigene complex from Enterococcus faecalis en-
coded on Tn1546 and results in the alteration of peptidoglycan
terminal stem peptide from D-Ala–D-Ala to D-Ala–D-Lac, a
structure to which glycopeptides no longer bind efficiently and
therefore fail to block transglycosylase and transpeptidase cell
wall cross-linking (47, 57). Worldwide, only a few examples of
VRSA have been reported (55).
In contrast, endogenous resistance to glycopeptides is much
more prevalent. S. aureus displaying intermediate glycopeptide
resistance (termed VISA if referring to vancomycin-interme-
diate S. aureus and GISA for glycopeptide-intermediate S.
aureus encompassing both vancomycin and teicoplanin) are
thought to arise stepwise from so-called heterogenous (hVISA
and hGISA) precursor populations through selection of muta-
tion(s) during the course of exposure to glycopeptides (28, 29,
43, 47). Rare subpopulations of bacteria displaying higher lev-
els of resistance presumably serve as a reservoir driving the
eventual emergence of glycopeptide resistance. Subpopula-
tions of this type are difficult to detect, and no routine clinical
laboratory tests exist that are standardized and reliable for
their detection (29, 61).
The MIC breakpoint defining the transition from sensitive to
intermediate resistant for glycopeptide intermediate-resistant
S. aureus (GISA and VISA) is not universally agreed upon;
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however, relatively minor alterations in reduced sensitivity to
glycopeptides (minor changes in MIC) are now frequently as-
sociated with clinical failure, requiring recourse to alternative
pharmacotherapy (29).
The genetic basis of endogenous glycopeptide resistance is
poorly understood. Mutation in genes such as tcaA, graRS, and
vraRS have been described and are known to be causal or
strongly correlated to the emergence of VISA and GISA (15,
30, 45, 48, 53). In some, but not all cases, morphological
changes associated with the emergence of glycopeptide resis-
tance include a thickened cell wall, reduced cross-linking, and
decreased autolytic activity, suggesting that complex alter-
ations in cell wall biosynthesis and turnover underlie the resis-
tance mechanism (27, 47, 57).
Transcriptomic studies demonstrated that an encounter with
cell wall-active antibiotics elicits a cell wall stress response in S.
aureus (22, 40, 46, 49, 51, 73). The precise mechanisms that are
responsible for the detection of cell wall damage are also
poorly understood, and there are known significant interstrain
variations (49).
In several studies, the transcriptional induction of the vraRS
two-component sensor (TCS) system, which is part of a four-
gene operon, is significantly induced after encounter with cell
wall-active drugs such as oxacillin, vancomycin, teicoplanin,
and D-cycloserine (22, 40, 49, 69, 77). The vraRS operon is also
strongly induced after reduced transcription of pbp2, which
encodes the bifunctional penicillin-binding protein PBP2 (22).
The VraRS TCS is highly conserved in the low-percent GC
Gram-positive family Firmicutes. In S. aureus, the VraRS TCS
is thought to regulate numerous genes, some necessary for cell
wall biosynthesis and proteolytic quality control (40). At least
two other S. aureus TCS systems—WalKR (YycFG) and
GraRS—have been implicated in modulating resistance to cell
wall-active antibiotics (16, 18, 30, 53, 63).
TCS systems are widespread in bacteria and represent envi-
ronmental sensing systems that integrate a broad range of
input stimuli to effector proteins, often including transcription
factors (20, 21). A typical TCS system is composed of a mem-
brane sensor histidine kinase and a cognate response regula-
tor. Environmental signal captured by the receptor kinase re-
sults first in histidine autophosphorylation. In a second step,
phosphotransfer from the histidine kinase to a conserved as-
partate in the receiver domain of the cognate response regu-
lator ultimately culminates in alterations in downstream gene
expression, or altered enzymatic activity, appropriate to the
applied stimulus.
In the present study, we dissected the VraRS phospho-
transfer sensing mechanism. We identified the key elements
of VraS-VraR phosphotransfer in vitro and examined genetic
consequences in vivo by using a site-specifically engineered
vraS autophosphorylation-defective chromosomal point muta-
tion. Our results reveal a crucial role for VraS-VraR signaling
in mediating the emergence of endogenous glycopeptide resis-
tance.
MATERIALS AND METHODS
Bacterial strains and plasmids. The strains and plasmids used in the present
study are listed in Table 1. Antibiotics and their suppliers were as follows:
teicoplanin (Sanofi Aventis), vancomycin (Sandoz), and oxacillin, D-cycloserine,
and carbenicillin (Sigma).
Cloning and purification of recombinant VraR and VraS proteins. The open
reading frame of the vraR gene (SA1700 using the N315 ordered sequence tag
numbering [41]) and the nucleotide region encoding the cytoplasmic domain of
the vraS gene (corresponding to amino acids 65 to 347), hereafter referred to as
VraScyt, were amplified by the PCR using S. aureus genomic DNA and primers
indicated in Table 2. Fragments of 884 bp (vraS) and 650 bp (vraR) were cleaved
with KpnI and PstI and cloned into the KpnI and PstI sites of pKSIIBluescript,
respectively. After sequence verification, the fragments were excised with NdeI-
PstI and cloned into the Escherichia coli expression vector pTYB12 (New En-
gland Biolabs). Recombinant VraR and VraScyt proteins were then purified by
using an N-terminal chitin affinity tag (Impact System; New England BioLabs).
E. coli strain ER2566 containing pTYB12-VraR and pTYB12-VraScyt was grown
in Luria-Bertani medium containing carbenicillin at 100 g/ml until reaching an
optical density at 600 nm of 0.4, induced with 0.5 mM IPTG (isopropyl--D-
thiogalactopyranoside), and incubated for an additional 6 h at 30°C with vigorous
shaking. Bacteria were harvested by low-speed centrifugation and resuspended in
buffer containing 0.1% Tween 20, followed by affinity chromatography and in-
tein-mediated proteolytic cleavage of the affinity tag with 50 mM dithiothreitol
(DTT) according to the manufacturer’s recommendations. Thiol-induced intein
cleavage resulted in the N-terminal attachment of three additional amino acids
(Ala-Gly-His) for VraR and four amino acids (Ala-Gly-His-Met) for VraScyt
upstream of Ser65. Cleaved protein was eluted from the chitin beads, and the
supernatant was concentrated and diafiltered using Centricon-10 spin columns.
Protein concentrations assuming monomer molecular weights predicted from the
amino acid composition were determined using Bradford reagent (Bio-Rad) and
a bovine serum albumin standard. Recombinant proteins were stored at 4°C and
were stable for at least 6 months.
QuikChange PCR mutagenesis (Stratagene) was used to create additional
protein expression vectors by a similar strategy as described above for mutants
VraR-D55A, VraScyt-H156A, and VraScyt-H238A (Table 2). All protein expres-
sion vector constructs were sequence verified prior to use. This purification
strategy was used for the preparation of each mutant recombinant protein.
Autophosphorylation and phosphotransfer assay. To assess histidine auto-
phosphorylation, 5 M concentrations of either VraScyt, VraScyt-H156A, or
VraScyt-H238A were incubated with 20 Ci of [-32P]ATP (Hartmann Analytics,
FP-301, 111 TBq/mmol) at 22°C in a 70-l labeling reaction containing 25 mM
Tris-HCl (pH 7.0), 2.5 mM MgCl2, 100 mM KCl, 0.1 mM DTT, 5% glycerol, and
20  cold ATP. Aliquots (10 l) were removed after 5, 15, and 45 min and
transferred to an equal volume of 2 sodium dodecyl sulfate (SDS) sample
loading buffer and applied to 12% polyacrylamide-SDS protein gels (without
heating). Protean II minigels (Bio-Rad) were electrophoresed at 11 W for 2 to
3 h. The gels were dried and autoradiographed (Amersham Hyperfilms). For
phosphotransfer reactions between VraS and VraR, an VraScyt or VraScyt-
H238A labeling protocol identical to that described above was used. After 45 min
of VraS autophosphorylation, 40 l was mixed with either purified VraR or with
VraR-D55A to a final concentration of 17.5 . Aliquots (10 l) were removed
and mixed with an equal volume of 2 SDS sample buffer and applied to SDS
protein gels as described above. Control phosphorylation reactions run in par-
allel and stained with Coomassie brilliant blue showed that all recombinant
proteins were stable under the conditions of the in vitro assay.
Total RNA extraction. Overnight bacterial cultures were diluted 1:100 and
grown at 37°C for 1 h in Mueller-Hinton broth (MHB) with shaking. When
indicated, oxacillin (1 g/ml; ISP794 MIC  2 g/ml; thus, conducted at 0.5
MIC) was added, and bacteria were grown for an additional hour. Bacteria were
harvested, and RNA extraction and verification of the absence of contaminating
DNA was performed as described previously (59). Purified RNA samples were
analyzed by using the RNA NanoLab chip on a 2100 Bioanalyzer (Agilent, Palo
Alto, CA).
Real-time RT-PCR. mRNA levels were determined by quantitative RT-PCR
(qRT-PCR) by using a one-step reverse transcriptase qPCR master mix kit
(Eurogentec, Seraing, Belgium), as described previously (59). Appropriate vraR
and vraS primers and probes were designed by using Primer Express software
(version 1.5; Applied Biosystems) and obtained from Eurogentec. The mRNA
levels of target genes extracted from the different strains were normalized to 16S
rRNA levels, which were assayed in each round of qRT-PCR as internal controls
as described previously (74). The statistical significance of strain-specific differ-
ences in normalized cycle threshold (CT) values of each transcript was evaluated
by using a Student paired t test, and data were considered significant when P was
0.05.
Northern blotting. For transcript analysis, 6 g of total RNA was separated in
a 1% agarose formaldehyde gel and blotted onto a nylon membrane (Hybond-N
Amersham) using 20 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium
citrate) buffer (Quantum Biotechnologies) with a semidry blot apparatus (Bio-
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Rad). The membrane was prehybridized with QuikHyb buffer (Stratagene) for
2 h at 65°C. An [	-32P]UTP (Hartmann Analytics, FP-110, 15 TBq/mmol)-
labeled vraR riboprobe was generated from pAM1158. After plasmid lineariza-
tion with Acc65I and gel purification, an [	-32P]UTP-labeled complementary
antisense transcript was produced by in vitro transcription using T7 polymerase
essentially as described previously (35). Unincorporated nucleotide was removed
by passage over a microspin ProbeQuant G-50 column (GE Healthcare). The
riboprobe mixture was treated with DNase I (Promega RQ1) to eliminate tem-
plate DNA, extracted with phenol-chloroform-isoamyl alcohol (25:24:1), and
precipitated with ethanol in the presence of 16 g of glycogen carrier. The pellet
was washed with ice-cold 70% ethanol, dried, and resuspended in a minimal
volume of Tris-EDTA. An aliquot was tested for probe purity on a 6% poly-
acrylamide 8 M urea sequencing gel. The prehybridized membrane was incu-
bated overnight with the vraR riboprobe at 65°C in the same QuikHyb buffer.
Washes were done as follows: a first wash at 50°C with 2 SSC–0.1% SDS for 15
min, a second wash with 1 SSC–0.1% SDS for 15 min at 65°C, and then three
washes with 0.1 SSC–0.1% SDS for 15 min at 70°C. The membrane was
transferred to 3MM paper without drying, sealed, and autoradiographed (Am-
ersham Hyperfilms).
Construction of AR756 containing a vraS disruption. To facilitate the con-
struction of a site-specific codon change VraS H156A by allelic exchange, a
chromosomal vraS disruption mutant was first constructed by deletion of the vraS
coding sequence corresponding to amino acids 2 to 160 (inclusive) and insertion
of an erythromycin resistance gene using the temperature-sensitive vector pBT2
(11). Briefly, a 1,076-bp upstream fragment and a 1,185-bp downstream fragment
were separately amplified by using the primer pairs presented in Table 2; the
products were then mixed and reamplified with the outside primers to create the
fusion PCR-generated internal deletion of vraS and cloned into pUC18-digested
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant genotype or characteristicsa Source or reference(s)
Strains
E. coli
ER2566 IPTG-inducible T7 RNA polymerase restriction-deficient DNA cloning strain New England Biolabs
DH5	 Gibco-BRL
S. aureus
COL MRSA, rsbU 24
RN4220 8325-4, r
 m, restriction-defective laboratory strain 38
Newman ATCC 25904, MSSA, rsbU 1
MB211 8325, (rsbUVW-sigB), tetL nearby 23
MB212 8325, rsbUVW-sigB::ermB 39
ISP794 8325, pig-131 rsbU mutant 60, 67
ALC1001 RN6390 sigB::Tn551 13
ALC2057 RN6390 sarA::kan 14
AR850 ISP794, rsbUVW-sigB::ermB This study
AR851 ISP794, sigB::Tn551 This study
AR852 ISP794, (rsbUVW-sigB), tetL nearby This study
AR756 ISP794, vraS2-160::ermB This study
AR769 ISP794, vraS(H156A), Kanr nearby This study
AR758 ISP794, Kanr within intergenic region SA1699-vraR This study
AR943 ISP794, tetK within intergenic region SA1699-vraR This study
AR828 ISP794, vraS(H156A), Kanr nearby, 11 transduction from AR769 This study
AR878 ISP794, vraS(H156A), Kanr nearby  pAM1483 This study
AR872 ISP794, vraS(H156A), Kanr nearby  pAM902 This study
AR848 Newman, vraS(H156A), Kanr nearby, 11 transduction from AR769 This study
AR868 COL, vraS(H156A), Kanr nearby, 80	 transduction from AR769 This study
Plasmids
pCL84 tetK; S. aureus geh locus integrating plasmid 42
pUC18 Multicopy E. coli cloning vector 76
pUC19-MuSupF Ampr mini-Mu transposon 26
pEC2 ermB cassette 11
pMK4 E. coli-S. aureus shuttle vector; Ampr Camr 70
pBT2 E. coli-S. aureus thermosensitive shuttle vector; Ampr Camr 11
pTYB12 N-terminal fusion Impact intein and chitin-binding domain plasmid New England Biolabs
pKSIIBluescript Routine multicopy E. coli cloning vector Stratagene
pAM1118 pKSII VraScyt (NdeI-PstI) This study
pAM1158 pKSII VraR (NdeI-PstI) This study
pEG1129 pTYB12-VraScyt (NdeI-PstI) This study
pEG1 pTYB12-VraScyt H156A This study
pEG2 pTYB12-VraScyt H238A This study
pEG1055 pTYB12-VraR (Nde-Pst) This study
pEG3 pTYB12-VraR-D55A This study
pAR712 pBT2, vraS-Kanr-SA1699 intergenic ts shuttle vector This study
pAR907 pBT2, vraS-tetK-SA1699 intergenic ts shuttle vector This study
pAM1284 pBT2, vraS2-160::ermB ts shuttle vector This study
pAR747 pBT2, vraS(H156A), Kanr nearby ts shuttle vector This study
pAM1483 pMK4, 3.3-kb entire vraR operon and upstream promoter region, KpnI-PstI This study
pAM1246 pKSII, 3.3-kb entire vraR operon and upstream promoter region, KpnI-PstI This study
pAM902 pMK4, pGlyS gfpuv4 72
a Camr, chloramphenicol resistance; Ampr, ampicillin resistance; Kanr, kanamycin resistance.
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by using KpnI and PstI. The erythromycin resistance ermB cassette was obtained
by BamHI digestion of a mini-Mu transposon derivative of pUC19-MuSupF (26)
harboring the ermB gene subcloned with linkers from pEC2 (11). The BamHI
ermB fragment was cloned into the unique BglII site. A plasmid with the tran-
scriptional orientation of ermB oriented in the same sense as the native vraR
operon transcript was chosen, digested with KpnI, and partially digested with
PstI, and then the 3.7-kb fragment was cloned into pBT2 to yield pAM1284.
Plasmid pAM1284 was electroporated into the restriction-defective strain
RN4220 and then transferred by electroporation into ISP794, selecting for eryth-
romycin resistance at 30°C. ISP794 containing pAM1284 was grown overnight at
30°C, followed by growth with applied marker selection for 6 days with dilution
passages at 42°C, a nonpermissive temperature for pBT2 replication. Bacteria
were plated on agar containing 5 g of erythromycin/ml and then replica
streaked on 15-g/ml chloramphenicol plates to screen for chloramphenicol-
sensitive colonies. Double-crossover events corresponding to vraS gene disrup-
tion was confirmed by PCR. The resulting strain was named AR756.
Generation of AR769 containing the vraS(H156A) mutant. The site-specific
chromosomal two-nucleotide change for the creation of vraS(H156A) was con-
structed using the thermosensitive plasmid pBT2 as follows. A KpnI-BglII over-
lap PCR fragment of 2,700 bp was amplified from ISP794 using the primers
SA1703KpnBamHI, H156A-B, H156A-A, and 12ABgl2 (Table 2). The overlap
PCR fragment spanning the region from SA1703 gene to the vraR-SA1699
intergenic region contains the nucleotide changes in positions 466 (C to G) and
467 (A to C) of the vraS open reading frame, resulting in the H156A codon
change. A second downstream PCR fragment was amplified by using the primer
pair 12BBgl2 and SA1699EcoPst (Table 2) incorporating BglII and PstI restric-
tion sites covering 1,300 bp from the vraR-SA1699 intergenic region and the
adjacent SA1699 gene. The fragments were cloned together in a three-piece
ligation with KpnI-PstI-digested pBT2. The unique BglII restriction site thus
engineered in the vraR-SA1699 intergenic region was used to insert a kanamycin
resistance marker obtained by PCR amplification from strain ALC2057 and in-
corporating terminal BamHI restriction sites (60). The site-specific vraS(H156A)
codon change gene targeting plasmid was named pAR747 and was fully sequence
verified.
Plasmid pAR747 was passaged through the nonrestricting strain RN4220,
followed by recovery and electroporation into AR756, selecting for kanamycin
resistance (Kanr) at 30°C. A single colony was isolated and subjected to kana-
mycin selection for 6 days with regular dilution and subculture passages at 42°C.
Bacteria were plated on agar containing 40 g of kanamycin/ml and then replica
streaked on 15-g/ml chloramphenicol and 5-g/ml erythromycin plates to
screen for the Kanr and erythromycin-sensitive (Erys) double-crossover events
corresponding to the expected vraS allelic exchange. A single colony was grown
and confirmed by PCR and sequencing. The resulting strain harboring
vraS(H156A) and its nearby linked Kanr marker to facilitate bacteriophage-
mediated cotransduction was named AR769. Bacteriophage 80	 was used to
backcross the kanamycin-linked vraS(H156A) allele to ISP794 to yield AR828
(95% cotransduction). For both AR769 and AR828, the entire chromosomal
3.3-kb vraR four-gene operon, including 600 bp of upstream promoter sequence
from the SA1703 ATG start codon, was sequence verified. Both strains had only
the desired vraS(H156A) codon change. Bacteriophage80	 and11 were used
to backcross the kanamycin-linked vraS(H156A) allele to strains COL and New-
TABLE 2. Oligonucleotide PCR primers used in this study
Gene, mutant, protein,
or method Primer or probe Primer sequence (5–3)
a
VraR wild-type protein VraR-Kpn-Nde GGGGTACCAAGGAGGAACACATATGACGATTAAAGTATTG
VraR-Pst CAAACTGCAGCTATTGAATTAAATTATGTTGGAATGC
VraR-D55A protein VraR D55A-A GATTTAATTTTAATGGCTTTACTTATGGAAG
VraR D55A-B CTTCCATAAGTAAAGCCATTAAAATTAAATC
VraScyt wild-type protein VraScyt-KpnNde PCR GGGGTACCAAGGAGGAACACATATGGGTTCGGTACTCGCATACAAAATC
VraScyt-Pst PCR CAAACTGCAGTTAATCGTCATACGAATCCTC
VraS-H156A protein VraS H156A-A GCTCGAGAACTTGCCGATTCTGTTAGTC
VraS H156A-B GACTAACAGAATCGGCAAGTTCTCGAGC
VraS-H238A protein VraS H238A-A ATGAAAGTTGTGGCTGAAATACAAGATTTTAAAG
VraS H238A-B CTTTAAAATCTTGTATTTCAGCCACAACTTTCAT
VraS2-160::ermB SA1703 Kpn-Bam GGGGTACCGGATCCATGAACTATGTTGAACGTTATATTGAACAG
Primer 2 Bam CGGGATCCGTTCATCGATAAATCACCTCTACG
Primer 3 Bam CGGGATCCCAGCAACTTTTTGCGGCAAGTATGA
SA1699 staEco-Pst CGGAATTCCTGCAGATGTCGAAAAATCACTCTTCTTCAAAATACC
VraS-H156A chromosomal SA1703KpnBamHI GGGGTACCGGATCCATGAACTATGTTGAACGTTATATTGAACAG
mutant SA1699EcoPstI CGGAATTCCTGCAGATGTCGAAAAAGGATCACTCTTCTTCAAAATACC
Kan marked vraR-SA1699 3BKpnBamHI GGGGTACCGGATCCCAGCAACTTTTTGCGGCAAGTATGATGC
intergenic 12ABgl2 GAAGATCTCGTAAGTAACTTTTCTTAATTCGATACG
12BBgl2 GAAGATCTCCAATCACAATATAACATCAAATAGACAC
SA1699EcoPstI CGGAATTCCTGCAGATGTCGAAAAAGGATCACTCTTCTTCAAAATACC
Upstream vraR operon EYKpn GGGGGTACCACTTTGATCCAAAAGACAAAACA
promoter Tet marker upF CGGGATCCGCTTCACAGAAATTCTAGAAC
Tet marker downR ACGCGTCGACTTTTATTACCTACAACTTCTTTA
Kan marker upF CGGGATCCGATAAACCCAGCGAACCATTTG
Kan marker downR CGGGATCCATCGATACAAATTCCTCGTAGG
qRT-PCR VraR-450 forward TGCTTACAGAACGAGAAATGGAAA
VraR-535 reverse CCGTTTTAATAGTAATATGCGATGCA
VraR-473T
(TAMRA-FAM)
TGATTGCGAAAGGTTACTCAAATCAAGAAAT
a Underlined regions represent restriction enzyme sequences.
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man, yielding strains AR868 and AR848, respectively. The presence of the
vraS(H156A) allele in each derivative strain was verified by sequencing.
Construction of AR758 and AR943 containing a kanamycin- or tetracycline-
marked wild-type vraR operon. Identical targeted insertions of only the kanamy-
cin resistance gene, or a tetracycline resistance gene, inserted nearby the vraR
operon in the intergenic region between vraR and SA1699, were obtained using
pBT2 as described above. Briefly, the regions 1,200 bp downstream and 1,300 bp
upstream from chromosomal location 1946712 (using sequence coordinates
based on N315 annotation [41]) were amplified by using the primer pairs de-
scribed in Table 2. The kanamycin resistance marker was obtained by PCR
amplification as described above. A BglII tetracycline resistance marker cassette
was obtained as described previously (60). The desired double-crossover events
were identified by screening for kanamycin/tetracycline-resistant but chloram-
phenicol-sensitive colonies. Correct insertion of the markers into the intergenic
region was confirmed by PCR and sequencing.
Constructions of rsbU and sigB mutant derivatives of ISP794. The wild-type
rsbU allele was restored in ISP794 by 80	 bacteriophage transduction of the
tetL-linked (rsbUVW-sigB) operon from donor strain MB211 and selection for
tetracycline to yield AR852. ISP794 derivatives lacking a functional sigB gene
(AR851) or disrupted for the entire rsbUVW-sigB operon (AR850) were con-
structed by 80	 bacteriophage transduction using the donor strain ALC1001 or
MB212, respectively. The restoration of rsbU in strain ISP794 was monitored
both by the reappearance of yellow-orange pigmentation and by the presence of
a functional B monitored by using a qRT-PCR assay of the B-dependent
transcription of asp23 (23, 39, 59).
Genetic assays for the emergence of glycopeptide resistance. Tests for the
emergence of glycopeptide resistance were performed essentially as described
previously (60). Briefly, overnight cultures of each strain to be tested were grown
in MHB at 37°C with vigorous agitation. Each bacterial culture was subsequently
normalized using sterile 0.9% (wt/vol) NaCl to McFarland standard 2 by using a
Densimat apparatus (bioMe´rieux, France). Aliquots (500 l, 1.5  108 CFU)
were spread on MHB agar containing various concentrations of freshly prepared
teicoplanin or vancomycin, followed by incubation for 48 h at 37°C. To determine
the relative efficiency of colony formation, serial dilutions of each culture were
also plated on MHB plates without drug. For each strain background—ISP794,
Newman, or COL—an emergence assay was performed using drug concentra-
tions determined from pilot experiments to be at or above the broth macrodi-
lution MIC. (Specifically, for teicoplanin these consisted of an ISP794 MIC of 1
to 2 g/ml, with an emergence assay performed at 2 g/ml; a Newman MIC of
1 to 2 g/ml [although the emergence assay was performed at 4 g/ml because
pilot experiments showed that plates were nearly confluent if selection at 2 g/ml
was applied]; and a COL MIC of 8 g/ml, with an emergence assay performed
at 8 g/ml. For vancomycin, they were an ISP794 MIC of 1 to 2 g/ml, with
an emergence assay performed at 2 g/ml; a Newman MIC of 2 to 4 g/ml,
with an emergence assay performed at 2 g/ml; and a COL MIC of 2 to 4
g/ml, with an emergence assay performed at 2 g/ml.) Broth macrodilution
MIC assays were performed as described previously (60). The data were tabu-
lated as the number of viable colonies at each drug concentration tested and
normalized per McFarland unit. The sum of CFU obtained on selective media in
multiple experiments was reported, together with the mean emergence frequency
defined as the ratio of normalized McFarland standard 1 CFU obtained on
selective media divided by the number of CFU obtained on nonselective media.
A subset of colonies was retested by replica plating on selective agar plates to
estimate the percentage of false positives arising in each experiment. The raw
data are reported without correction, and thus calculated emergence frequencies
represent an upper limit.
Genetic complementation of vraS(H156A). Strain AR828 was transformed
with the empty E. coli-S. aureus shuttle plasmid pMK4 or pMK4 containing the
entire cloned 3.3-kb vraR operon, together with native upstream promoter se-
quences (pAM1483). The genomic vraR operon fragment was obtained by PCR
amplification using the primers EYKpn and VraR-Pst (Table 2) and Pfx poly-
merase (Invitrogen). The entire vraR operon was sequence verified using the
appropriate primers. The functional restoration of induction of the vraR operon
after challenge with oxacillin was performed as described above and monitored
by qRT-PCR assay using a vraR TaqMan probe.
RESULTS
Prediction of the VraS H-box region and protein purifica-
tion. Phylogenetic and functional studies of histidine kinase
sensors have revealed several highly conserved motifs within
the cytoplasmic kinase domain (21). The motifs comprise two
distinct domains: a HisKA domain containing the H-box and a
conserved histidine residue that serves as the site of autophos-
phorylation, as well as a C-terminal domain termed HATPase
within which are found boxes named N1, G, F, G2, and G3 that
comprise the ATP-binding pocket (54).
Multiple sequence alignment using T-Coffee and CLUSTAL
W2 algorithms (http://www.expasy.org/tools/proteome) were per-
formed using the S. aureus VraS sequence and a panel of bacterial
HK sensors. We identified one region, ARELH156DSVSQ, which
was similar to the H-box region of eight HK sensors subclas-
sified as type III (36). In addition, sequence context inspection
of all other histidines revealed a second potential histidine
autophosphorylation site, VVH238EI, which was highly similar
to the VSH249EI found in the S. aureus TCS HssRS system
(68). A schematic diagram summarizing the predicted domain
architecture of VraS is shown in Fig. 1.
We cloned the region comprising the predicted cytoplasmic
domain of VraS, amino acids 65 to 347, hereafter referred to as
VraScyt. The N-terminal 64 amino acids of VraS are very rich
in hydrophobic residues, and this region is thought to comprise
the transmembrane anchor sequence (Fig. 1). The precise to-
pological configuration of the transmembrane region is un-
known, as are the amino acids responsible for sensing external
signals. To purify VraScyt, we designed PCR primers (Table 2)
that incorporated both NdeI and PstI restriction sites appro-
priately positioned to permit cloning in pTYB12 (NEB). A
recombinant hybrid VraScyt protein was produced in E. coli as
an N-terminal intein fusion. Protein was purified by chitin
affinity chromatography, cleaved in situ using DTT, eluted,
and concentrated (see Materials and Methods). Thiol-induced
cleavage resulted in the release of VraScyt containing four
additional N-terminal amino acids: Ala, Gly, and His due to
the intein self-cleavage recognition sequence, together with a
Met introduced by the NdeI restriction site. A similar strategy
was used to purify two variants of VraScyt in which histidines
H156 and H238 had been separately replaced by alanine and
named H156A and H238A (Fig. 1).
As a substrate for the detection of phosphotransfer by
VraScyt, we used the same intein fusion protein strategy to purify
wild-type VraR and a point mutant, VraR-D55A. Purified
VraR and VraRD55A also possessed an additional N-terminal
three amino acids, Ala-Gly-His, after thiol cleavage.
Aliquots of purified proteins were examined by Coomassie
blue staining after electrophoresis in 12% polyacrylamide-SDS
gels and judged to be 99% pure (Fig. 2). Purified wild-type
and mutant VraScyt proteins all comigrated with an apparent
mass of 34 kDa, which is consistent with the predicted 34-kDa
molecular mass for this fragment. Purified wild-type VraR and
VraR-D55A both comigrated in SDS-PAGE with an apparent
molecular mass of 22 kDa, which is slightly smaller than the
predicted 24 kDa for this fragment. Purified proteins were
stable for at least several months at 4°C.
Determination of the site of VraS autophosphorylation. To
examine the ability of each VraScyt protein to undergo auto-
phosphorylation in vitro, samples were incubated in the pres-
ence of [-32P]ATP, and aliquots were removed at various
times, resolved on 12% polyacrylamide SDS gels, dried, and
autoradiographed. The results are shown in Fig. 3A.
We observed a progressive increase in the intensity of radiola-
beled wild-type VraScyt indicating autophosphorylation that
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reached an apparent plateau at 45 min. We observed a similar
autophosphorylation of VraScyt H238A, which also showed a pla-
teau after 45 min of incubation. The relative intensity of VraScyt
and H238A autophosphorylation seen in the representative
autoradiogram is most likely due to experimental conditions,
or perhaps to altered protein specific activity. We did not
further explore the exact cause of this discrepancy. In contrast,
to the results obtained with VraScyt and H238A, we observed
no detectable autophosphorylation of the H156A variant un-
der identical conditions and replicate experiments.
We conclude from this analysis that VraS H156 is essential
for autophosphorylation of the purified VraScyt fragment in
vitro and that this site most probably represents the site of
autophosphorylation. The arrangement and position of con-
served amino acid residues in the N, G1, G2, and G3 regions
of the VraS cytoplasmic domain fragment are coincident when
comparing VraS alignment with other sensor kinase proteins
such as Escherichia coli NarX and UhpB or Haemophilus in-
fluenzae NarQ (Fig. 1). The absence of an F region, together
with the 108-amino-acid spacing between H156 and N strongly
FIG. 1. Schematic diagram of VraS and VraR highlighting their domain architecture and the location of amino acids mutated in the present
study. The predicted transmembrane region (TM), histidine kinase (HisKA), and histidine kinase ATP-binding domain (HATPase) are shown.
VraScyt indicates the point of truncation used for the purification of the cytoplasmic and soluble portion of the protein used in the present study.
The VraR response regulator is depicted and shows the receiver domain and position of phosphorylated aspartate, along with the C-terminal
DNA-binding domain. The sequence alignment shows the H-box sequence context of VraS-H156, together with other conserved motifs within the
ATP-binding domain. Sequences used were from Swiss-Prot accession: Staphylococcus aureus VraS, Q99SZ7; Bacillus subtilis LiaS, O32198;
Escherichia coli UhpB, P09835; and Haemophilus influenzae NarQ, P44604.
FIG. 2. Purified VraR and VraS and their indicated mutant deriv-
atives used in the present study. Proteins were resolved on 12% poly-
acrylamide-SDS gels and stained with Coomassie brilliant blue. Mo-
lecular mass standards are indicated in kilodaltons for the marker
ladder.
FIG. 3. In vitro autophosphorylation and phosphotransfer assay
using purified VraS and VraR. (A) VraS autophosphorylation time
course assay in the presence of [-32P]ATP. Reactions were assembled
for the indicated times and applied to 12% polyacrylamide-SDS gels,
dried, and autoradiographed. Wild-type VraS lacking the N-terminal
transmembrane domain VraScyt and two purified histidine mutants,
H156A and H238A, are shown. (B) VraS-VraR phosphotransfer assay.
Autophosphorylation reactions were performed as described for panel
A, and then VraR was added. Aliquots were removed at the indicated
times and resolved on SDS-protein gels as described above. Note that
a minor phosphorylated degradation product of VraS migrates at a
position above phosphorylated VraR. S, VraS; R, VraR.
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suggests the classification of VraS as HK subtype type III and
kinase type unorthodox (36).
VraS histidine kinase phosphotransfer assay. Alignment of
response regulators from multiple bacteria has consistently
revealed a highly conserved acidic pocket positioned at the top
of the characteristic 	55 protein fold of the receiver domain.
An aspartate side chain within the pocket serves as an acceptor
for phosphotransfer reaction from the cognate histidine kinase
receiver domain. Inspection of the VraR domain revealed that
D55A was most likely the site of phosphorylation. Using puri-
fied proteins and in vitro phosphotransfer assay, we demon-
strated that phosphorylated VraScyt can transfer its phosphate
to VraR but not to VraR-D55A (Fig. 3B). While the present
study was in progress, VraR-D55A was independently identi-
fied by mass spectrometry as the site of VraR phosphorylation
(3), thus confirming these results. Collectively, these findings
define key molecular details of the essential amino acid resi-
dues, VraS-H156 and VraR-D55, comprising the phosphorelay
network of the VraRS TCS system.
Targeted engineering of vraS(H156A) point mutation in
the S. aureus chromosome. To examine the functional conse-
quences of uncoupling VraS-VraR phospho-signaling in vivo,
we next constructed S. aureus strains (AR769 and AR828) in
which the vraS(H156A) mutation tagged with a nearby kana-
mycin resistance marker was stably introduced into the bacte-
rial chromosome. Another strain, AR758, containing only the
kanamycin marker within the VraR-SA1699 intergenic region,
but otherwise wild type for the entire vraSR operon, was de-
signed in parallel. The two-step strategy used for the genetic
engineering by allelic exchange of this targeted codon muta-
tion is depicted in Fig. 4.
A design feature that permitted efficient screening for the
kanamycin-linked vraS(H156A) mutation in strain AR769
was the prior construction of an intermediate strain, AR756,
that contained an internal deletion within vraS (Fig. 4B).
Kanamycin selection with the thermosensitive pAR747 tar-
geting plasmid resulted in a subset of colonies having lost
the ermB marker by allelic exchange, thus guaranteeing the
FIG. 4. Schematic showing the various genetic steps used for the construction of a chromosomal mutant encoding vraS(H156A) and marked
with a nearby kanamycin resistance cassette in the VraR-SA1699 (N315 ordered sequence tag numbering) intergenic region. A second strain
harboring only the kanamycin resistance marker, but otherwise wild type for the entire VraSR four-gene operon, was designed in parallel. A
thermosensitive shuttle plasmid, pAR747, was introduced into AR756. The correct double-crossover event yielded the desired vraS-H156 mutation
by allelic exchange. The vraS(H156A) allele was then backcrossed into strain ISP794 by bacteriophage-mediated transduction using selection for
the tightly linked nearby kanamycin marker to give AR828. The entire operon and upstream promoter sequences were completely sequence
verified. Arrows indicate the transcription direction. Kpn and Pst denote the positions of the restriction sites used for the construction of pAR747
targeting vector.
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chromosomal insertion of the desired vraS(H156A) muta-
tion (Fig. 4B).
Growth curves for ISP794, AR758, and the mutant strains
AR769 and AR828 were identical and indicated that under our
routine laboratory conditions, neither the introduction of a
kanamycin marker in the VraR-SA1699 intergenic region nor
the H156A codon change in VraS resulted in detectable al-
tered fitness (data not shown). Strains AR769 and AR828 were
both used interchangeably for subsequent in vivo experiments.
Northern blot analysis. To assess the effect of VraS-VraR
phosphotransfer uncoupling by the H156A mutation in vivo,
transcriptional induction of the vraR operon was monitored by
Northern blot and qRT-PCR analysis for strains ISP794 and
AR828 after challenge with subinhibitory amounts of cell wall-
active antibiotics.
Using a radiolabeled vraR probe, we observed a strong tran-
scriptional induction of the vraR operon in the presence of 0.5
MIC oxacillin as an inducer (Fig. 5A). We detected multiple
distinct bands by this Northern blot analysis, including the
longest transcript (2.7 to 3.0 kb) sufficient to encode the entire
operon (22, 40, 77). In contrast, transcriptional induction was
severely reduced in the mutant strain AR828. Similar results
were obtained with subinhibitory concentrations of D-cycloserine
and teicoplanin as cell wall stress inducers (data not shown).
Quantification of vraR mRNA levels by qRT-PCR analysis
confirmed the oxacillin-stimulated transcriptional induction of
the vraR operon. A small, but significant (P  0.05) residual
level of transcriptional induction (2-fold) was observed in the
vraS(H156A) mutant strain compared to its uninduced control
level (Fig. 5B). This result suggests the possibility that addi-
tional transcriptional regulatory circuits exist for this operon
that do not depend upon VraS-mediated signal transduction.
We next repeated the qRT-PCR assay using RNA extracted
from strains harboring the multicopy plasmid pMK4, or pMK4
containing the entire 3.3-kb vraR operon including native up-
stream promoter sequences (pAM1483). We observed strong
transcriptional induction of the vraR operon in the mutant
strain harboring pAM1483, but not pMK4 vector alone, in the
presence of subinhibitory oxacillin as described above (data
not shown). We conclude that the vraS(H156A) mutation is
recessive and that only the vraS(H156A) mutation accounts for
the observed loss of transcriptional induction in the experi-
ments described above.
Effect of vraS(H156A) on the frequency of emergence of
reduced sensitivity first step glycopeptide mutants. To test the
functional consequences in vivo of uncoupling VraS-VraR
phospho-signaling, we next examined whether the mutation
detectably altered the MIC, or the frequency with which resis-
tant colonies appeared on agar plates supplemented with var-
ious amounts of glycopeptide antibiotics. We reasoned that
uncoupling the VraS-VraR phosphotransfer sensory system
would significantly affect the detection of cell wall stress and
thus alter or abolish the emergence of glycopeptide-resistant
mutants.
We addressed this hypothesis using three S. aureus strain
backgrounds: ISP794 (an 8325 derivative defective in rsbU and
consequently lacking a normal alternative stress sigma factor
B pathway), Newman (rsbU), and COL (an rsbU MRSA
strain). The teicoplanin and vancomycin MICs were deter-
mined for ISP794, Newman, and COL, and the emergence
assay was designed to detect the number of viable colonies
arising on plates containing drug at the MIC determined for
each parental strain (see Materials and Methods). We ob-
served a significant MIC reduction in every case (Table 3).
Measurement of the oxacillin MIC for the MRSA strain COL
(MIC  400 g/ml) and AR868 (MIC 100 g/ml) indicated
that the vraS(H156A) mutation also significantly reduced me-
thicillin resistance in this strain background.
It is worthwhile to emphasize that the MIC values we report
FIG. 5. Transcriptional analysis showing the effects of uncoupling
of VraS phosphotransfer. (A) Northern blot analysis showing strong
oxacillin-induced induction of vraRS operon transcription in wild-type
cells but severe reduction in the vraS(H156A) mutant. Note that the
vraRS operon is autoregulated. The 2.7-kb band encodes the entire
four-gene operon. Estimated lengths of additional transcripts are in-
dicated that may represent strong pause sites or partial transcript
degradation. Ethidium bromide-stained 16S and 23S rRNAs are shown
as loading controls. (B) Quantitation of VraR mRNA levels by qRT-
PCR analysis showing that oxacillin-stimulated transcriptional induc-
tion of the vraRS operon is severely reduced but not completely abol-
ished by vraS(H156A). An asterisk denotes Student two-tailed t test
analysis of transcript levels in the presence or absence of oxacillin (P
0.05) from three independent determinations.
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throughout our studies here were determined using broth
macrodilution; this method may give higher values than
other susceptibility testing methods. Indeed, a recent study
conducted in our laboratory indicates that microdilution meth-
ods tend to underestimate glycopeptide resistance (75). Gly-
copeptide MIC values for both COL and Newman have also
been shown to be sensitive to experimental conditions (7, 66).
Some caution is warranted, therefore, for cross-comparison of
MIC values in the published literature since it is becoming
clear that inoculum size, growth medium, time of incuba-
tion, and method are important parameters that collectively
impact reported MIC values.
Next, for each parental strain tested, we observed the con-
sistent appearance of viable colonies on agar plates containing
various amounts of teicoplanin or vancomycin in the emer-
gence assay. The frequency of emergence was computed for
each strain and defined as the ratio of the number of colonies
appearing using a standardized bacterial inoculum applied to
each plate (1.5  108 CFU) under selective (TMIC or VMIC) or
nonselective (T0 or V0) conditions. We measured a frequency
of viable colonies (defined hereafter as emergence) by this
method predominantly in a range from 1.1  10
6 to 5.0 
10
8, depending upon the strain and applied selection (Table
4). Similar results were observed when vancomycin was used,
although we noted that the emergence frequency was lower for
this drug than for teicoplanin under our standard laboratory
conditions.
Colonies that arise in our emergence assay are either false
positives and do not grow under selective conditions upon
replating or represent stable mutants that do grow at or above
the original selective conditions upon replating. We estimated
the false-positive rate in multiple experiments by sampling
subsets of colonies and determined it to be in the range of 5 to
20%. The tabular data we report, however, reflect the sum-
mated raw data from multiple independent experiments with-
out correction for false-positive rate, which was not computed
for every experiment. Thus, the resulting calculation of resis-
tance frequencies yields an upper limit. In some cases, we also
examined the spread of MIC values of colonies that arose
during selection and which were classed as stable. For example,
ISP794 selected for growth on MH agar plates in the presence
of 2 g of teicoplanin/ml gave rise to a range of MICs from 2
to 8 g/ml (data not shown). Thus, colonies that grow at the
applied selection concentration and that are not false positive
show MIC values at or above the drug concentration used for
the initial applied selection.
In striking contrast to our results obtained with strains
harboring a wild-type vraS allele, we never observed colo-
nies arising in multiple independent trials using teicoplanin
selection for any of the three strains tested containing the
vraS(H156A) mutation. When using vancomycin selection, we
did not observe the appearance of resistant colonies with strain
ISP794; however, we did observe the appearance of several
viable colonies derived from strains Newman or COL (Table
4). The appearance of these infrequent colonies, whose van-
comycin resistance was confirmed by replating, indicated that
during selection with vancomycin the vraS(H156A) mutation
drastically reduced (by 2 log10) but did not entirely abolish
the emergence of resistant colonies in these strain backgrounds.
Control experiments with strains carrying only the kanamycin
resistance marker in the vraR-SA1699 intergenic region showed
equivalent emergence frequencies of drug-resistant colonies com-
pared to parental strains, thus ruling out any deleterious role for
this marker that could account for the observed abolition or
significant reduction in viable CFU for strains AR828, AR848,
and AR868 exposed to glycopeptides (data not shown).
To confirm that the abolition of the emergence of glycopep-
tide-resistant mutants was indeed the result of the vraS(H156A)
mutation, we performed a complementation analysis using
strains AR878 and AR872 containing multicopy plasmid
pAM1483 encoding the entire four-gene vraR operon or con-
taining pAM902 control vector harboring green fluorescent
TABLE 3. Effect of vraS(H156A) mutation on glycopeptide MIC
Strain
MIC (g/ml)a
Teicoplanin Vancomycin
ISP794 1–2 1–2
AR828 0.5 0.5
Newman 1–2 2–4
AR848 0.5 0.5–1
COL 4–8 2–4
AR868 0.5 0.5–2
a MIC assays were performed by using broth macrodilution. Note that discrep-
ancies (ranges) have been indicated for glycopeptide MICs that are method
dependent (75).
TABLE 4. Effect of vraS(H156A) mutation on emergence of glycopeptide resistance
Strain Description Relevantgenotype
Emergencea of:
Teicoplanin Vancomycin
CFU tot (n) FOE (TMIC/T0) CFU tot (n) FOE (VMIC/V0)
ISP794 MSSA, rsbU 5591 (9) 1.1  10
6 37 (3) 5.0  10
8
AR828 ISP794, vraS(H156A) MSSA, rsbU 0 (9) NC 0 (3) NC
AR878 ISP794, vraS(H156A), pAM1483 MSSA, rsbU 238 (3) 6.6  10
7 30 (3) 6.7  10
8
AR872 ISP794, vraS(H156A), pAM902 MSSA, rsbU 0 (3) NC 0 (3) NC
Newman MSSA, rsbU 504 (6) 4.0  10
7 200 (3) 2.0  10
7
AR848 Newman, vraS(H156A) MSSA, rsbU 0 (6) NC 1 (3) 7.6  10
10
COL MRSA, rsbU 626 (4) 8.0  10
7 456 (3) 3.5  10
6
AR868 COL, vraS(H156A) MRSA, rsbU 0 (4) NC 4 (3) 3.1  10
8
a The frequency of emergence (FOE) is expressed as the ratio of CFU under selective (TMIC or VMIC) and nonselective (T0 or V0) conditions computed as the mean
from the indicated number (n) of independent experiments. Each emergence assay was performed using MH agar and 1.5  108 applied bacteria per plate. CFU were
counted at 48 h and 37°C. False-positive rates of CFU detected in the emergence assay were found to be 5 to 20% depending upon the experiment. NC, not computed.
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protein (Table 4). The results revealed that restoration of
wild-type vraS coding sequence concomitantly restored emer-
gence of glycopeptide resistant mutants using either teicopla-
nin or vancomycin selection (Table 4). Similar results were
obtained in a second type of complementation analysis without
multicopy plasmid where we restored wild-type vraS in the
ISP794 genetic background by allelic exchange using bacterio-
phage-mediated transduction from AR943 (data not shown).
Collectively, we conclude from these results that the VraS-
VraR phosphotransfer uncoupling mutation vraS(H156A) abol-
ished the detectable emergence of teicoplanin-resistant colo-
nies and severely reduced the frequency of emergence of
vancomycin resistant colonies. Since the vraS(H156A) muta-
tion also alters COL resistance to oxacillin, we conclude that
uncoupling VraS-VraR phosphotransfer impacts S. aureus re-
sponse to at least two classes of antibiotics and can act both at
the level of blocking emergence or altering the sensitivity pro-
file of preexisting drug resistance.
Role of the alternative sigma factor B in the emergence of
glycopeptide resistance. The ISP794 strain and its derivatives
used routinely in our laboratory (8, 60) and also extensively for
studies of fluoroquinolone resistance (19) is a derivative of
8325 and carries an 11-bp deletion in rsbU. Because of this
mutation, ISP794 possesses impaired transcriptional responses
mediated by the alternative stress sigma factor B. A functional
B is thought to play a role in glycopeptide resistance (5, 7),
but its role in the early steps of emergence of drug resistance
have not been previously examined. Therefore, to test what
role, if any, B played in the emergence of glycopeptide resis-
tance in this strain background, we constructed three isogenic
derivatives of ISP794: AR850, AR851, and AR852, which were
characterized by deletion of the entire four-gene rsbUVW-sigB
operon, disruption of the sigB alone, or restoration of rsbU,
respectively. Each strain was tested in multiple independent
assays as described above. The results are shown in Table 5.
We observed that the deletion of the entire rsbUVW-sigB
operon, or sigB alone, did not abolish the emergence of teico-
planin-resistant colonies. In contrast, when rsbU was restored
in ISP794, we noted dramatic enhanced emergence frequency
compared to ISP794 (rsbU) conducted under identical con-
ditions. We conclude that a functional B markedly enhances
the emergence of glycopeptide resistance in this strain back-
ground but that B is not absolutely required for resistant
colonies to arise.
DISCUSSION
In this study, we have identified the amino acids, VraS H156
and VraR D55, involved in phosphotransfer signaling in the
VraRS TCS, a sentinel system for cell wall stress in S. aureus.
Importantly, we have found that three distinct strains—ISP794,
Newman, and COL, each genetically engineered to harbor
the mutation encoding autophosphorylation-defective VraS
H156A—are unable to generate first step low-level teicoplanin
resistance mutants at a detectable frequency. The mutation
also abolished detectable first-step low-level vancomycin-resis-
tant mutants in strain ISP794 and severely reduced the fre-
quency of mutants in Newman and COL strains. Disruption of
VraS-mediated signaling in these strains also significantly al-
tered the MICs of both teicoplanin and vancomycin as mea-
sured by broth macrodilution and also significantly altered the
oxacillin MIC in the MRSA strain COL.
A broad range of antibiotics provoke cell wall stress in S.
aureus and transcriptional upregulation of the vraSR four-gene
operon is a feature commonly observed (22, 40, 77). Recent
study provides a mechanistic explanation since VraR binds
directly to its own promoter and thus autoregulates itself (4).
Besides extensive evidence from transcriptome and sequence
analysis of clinical isolates that highlight the importance of
VraRS for glycopeptide resistance (9, 16, 22, 32, 34, 40, 46, 49,
52, 56, 73), additional mutations in the graRS TCS or tcaA
disruption promote glycopeptide resistance (10, 15, 30, 45, 48,
53). Transcriptional upregulation of the WalKR TCS is also
associated with altered glycopeptide resistance (31). Consider-
ing our inability to isolate first-step mutants using strains car-
rying the vraS(H156A) mutation, it is tempting to speculate
that a functional VraRS phosphotransfer signaling system is
necessary for all, or certainly a majority, of pathways leading to
the emergence of glycopeptide resistance. It is important to
stress, nevertheless, that the emergence assay that we describe
in the present study used selection at very low drug concen-
trations, and therefore the role of VraRS has not been system-
atically assessed under other selection conditions using, for
example, higher drug concentrations.
Several recent studies also provide evidence for glycopeptide
resistance arising as a consequence of genetic selection with
antibiotics other than glycopeptides. For example, selection of
S. aureus growth in the presence of imipenem or daptomycin
has been shown to produce strains with altered glycopeptide
resistance profiles (32, 33, 50). These results are also supported
TABLE 5. Effect of alternative sigma factor sigB on the emergence of glycopeptide resistance
Strain Description Relevant genotype CFU tot (n) FOEa (T2/T0)
MIC (g/ml)b
Teicoplanin Vancomycin
ISP794 rsbU 1,065 (3) 1.1  10
6 1–2 1–2
AR850 ISP794, sigB operon rsbUVW sigB::ermB 280 (3) 3.5  10
7 2 1
AR851 ISP794, sigB sigB::Tn551 633 (3) 8.0  10
7 1 1
AR852 ISP794, rsbU (rsbUVW-sigB), tetL nearby 3,000 (3)c 3.0  10
5d 2 2
a The frequency of emergence (FOE) was determined as described in Table 4, footnote a.
b Defined in Table 3, footnote a.
c Viable counts on agar containing 2 g of teicoplanin/ml were too high to accurately measure using these conditions compared to ISP794. More than 1,000 CFU
were estimated in each experiment.
d The value reported is an estimate of the lower limit using CFU data obtained under identical conditions for the frequency determined with ISP794.
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by clinical case reports suggesting that the mechanisms respon-
sible for altered sensitivity to daptomycin and the emergence
of hVISA are related (37, 71). In light of these findings, it is
conceivable that disruption of VraRS TCS signaling could also
predictably attenuate the emergence of glycopeptide cross-
resistance evoked by a nonglycopeptide drug encounter.
Derivatives of S. aureus strain 8325, such as ISP794 used in
our study, are known to have an 11-bp deletion in rsbU, and
consequently such strains display reduced availability of free
B, an alternative stress sigma factor that has been shown to
regulate more than 200 genes in response to a variety of stress
inducers (6, 23, 39). Free B is sequestered by the anti-sigma
factor RsbW and is thought to be released in times of stress by
the anti-sigma factor RsbV, provided it is dephosphorylated by
the RsbV-specific phosphatase, RsbU (65). The absence of a
functional RsbU in 8325 derived strains thus explains the con-
stitutive sequestration of B by RsbW. Previous studies (5, 7)
have hinted that B controls gene(s) required for glycopeptide
resistance in S. aureus and that teicoplanin exposure stress can
select for enhanced B activity. One recently identified B-
regulated gene contributing to reduced glycopeptide sensitivity
is spoVG, although its mechanism of action in S. aureus re-
mains to be clarified (64).
In our study, we examined the role of B specifically at the
level of the emergence of first step teicoplanin resistance mu-
tants and found that strains derived from ISP794 lacking sigB
(encoding B) or the entire rsbUVW-sigB operon were still able
to generate teicoplanin-resistant mutants, thus formally
demonstrating that a functional B was not strictly necessary
for the emergence of glycopeptide resistance in this strain
background. In contrast, the restoration of wild-type rsbU in
ISP794, and thus the concomitant restoration of fully func-
tional B stress response, led to markedly enhanced emergence
of teicoplanin resistance. Our inability to isolate first-step teico-
planin mutants in an ISP794 rsbU strain carrying vraS(H156A)
indicates that disrupting VraRS signaling can apparently override
any contribution to the emergence of low-level teicoplanin resis-
tance dependent upon B in this strain background.
Using quantitative transcript analysis, we have shown that
the vraS(H156A) mutation abolishes most, but not all tran-
scription induction of the vraSR operon after brief exposure to
a subinhibitory amount of oxacillin to provoke cell wall
stress. Only a single major transcription start site upstream
of SA1703, the first open reading frame of the four-gene
operon, has been detected by primer extension (77) and con-
firmed independently by our laboratory using 5 rapid ampli-
fication of cDNA ends (5RACE; A. Renzoni, unpublished
results). The vraRS operon is not known to be transcriptionally
regulated by B under any condition tested (6). We therefore
believe that additional regulatory pathways exist for this pro-
moter that are not governed by VraS-VraR phosphotransfer.
Experiments to uncover these accessory regulatory factors are
in progress.
The consequences of genetic disruption of vraS by inser-
tional inactivation or by deletion of the entire vraSR coding
region have been studied independently by several laboratories
(9, 16, 22, 40, 51, 56, 77). These reports link the loss of function
of VraRS to oxacillin resistance in C-MRSA, altered drug
sensitivity profiles in a range of clinical MSSA and MRSA
isolates, and disruption of VraR-dependent target gene acti-
vation such as pbp2. In addition, a growing inventory of clinical
hVISA and GISA isolates that have been partially sequenced
reveals numerous examples of missense mutations mapping in
vraS, vraR, or SA1702 (16, 32–34, 52). How missense mutations
such as VraS-I5N modify VraRS-dependent signaling and gene
expression is unknown. A reasonable hypothesis is that such
mutations result in enhanced activation of the VraRS signaling
pathway, even in the absence of an external inducing signal
such as drug stress. With the VraSR pathway set in an ON, or
semi-ON state, the cells realign their cell wall biosynthetic
machinery to survive in the presence of glycopeptide.
Our study clearly predicts that pharmacologically blocking
VraS signaling by interfering with its sensor histidine kinase
function will significantly block the emergence of glycopeptide
resistance or restore fully, or partially, sensitivity to glycopep-
tide antibiotics in strains showing preexisting reduced sensitiv-
ity to these drugs. The idea of using kinase inhibitors to target
bacterial TCS systems has been suggested for many years,
especially in light of the fact that TCS systems are not found in
humans (2, 25, 58, 62). Our genetic study reported here there-
fore provides a firm foundation for this strategy and further
predicts that the efficacy of existing antistaphylococcal cell
wall-active antibiotics might be prolonged if such kinase inhib-
itor compounds were to be ultimately identified and coadmin-
istered.
Evidence presented to date thus underscores the importance
of the vraRS operon at the crossroads mediating S. aureus
response to cell wall stress and cell wall-active antibiotics. The
ensemble of downstream events that are regulated by VraR-
dependent transcription may be quite extensive judging by the
number of genes suspected to be regulated by this system.
Additional response pathways mediated by other TCS systems
(AgrAB, GraRS, and WalKR) and global regulators such as B
would appear to contribute to the establishment of endoge-
nous glycopeptide resistance. By targeting the initial molecular
features of the VraRS signaling response pathway at the onset
of this multifactorial regulatory cascade, we strongly believe
that emergence of glycopeptide resistance could be contained.
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